ClinicalTrials.gg
CompletedNCT01537991I-STARTUpdated Jan 14, 2019

ISoToxic Accelerated RadioTherapy in Locally Advanced Non-small Cell Lung Cancer: The Phase I/II I-START Trial

An interventional study of Radiotherapy in Locally Advanced Non-small Cell Lung Cancer, sponsored by Lisette Nixon. Completed at 2 sites in United Kingdom. Open to participants aged 16 Years and older. Per ClinicalTrials.gov, last updated 2019-01-14.

Sponsored by Lisette Nixon · Not applicable, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
81
Allocation
Non-randomized
Ages
16 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 570 studies in Carcinoma, Non-Small-Cell Lung with a site in United Kingdom — 103 open to participants now, 202 under way, 94 of them phase 3. Carcinoma, Non-Small-Cell Lung · United Kingdom.

Enrollment
392nd of 522
81 · median 272
Started
2012
with 18 others
No phase
20 of 570
1 open now
Registered
150th of 570
by date

Among the 570 studies in Carcinoma, Non-Small-Cell Lung with a site in United Kingdom, this one is the 392nd largest by enrollment of the 522 interventional ones that give a count, is one of 19 that started in 2012, is one of 20 with no phase, and was the 150th registered.

Carcinoma, Non-Small-Cell Lung

7,639 studies on the registry are indexed under Carcinoma, Non-Small-Cell Lung; 1,838 are open to participants now.

Browse Carcinoma, Non-Small-Cell Lung studies →

Open to participants now

103 of the 570 studies in Carcinoma, Non-Small-Cell Lung with a site in United Kingdom are open now. Recruiting first, the newest first:

98 more — sign in →

All 103 open studies →

A study can be open while its sites in United Kingdom have not opened yet or have stopped. Only those recruiting at a site in United Kingdom →

Who these studies take

Of the 1,324 Carcinoma, Non-Small-Cell Lung studies recruiting now, 987 (75%) set no upper age limit and 225 (17%) stop at 75 or younger; 34 take children under 18; 40 take healthy volunteers.

This study: 16 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 570 studies in Carcinoma, Non-Small-Cell Lung with a site in United Kingdom, or all of them as a file.
02

Study summary

The I-START trial is designed to determine the highest doses of radiotherapy that can safely be used in locally advanced non-small cell lung cancer (NSCLC). Patients with NSCLC who are expected to live longer than three months and are fit to receive radical radiotherapy (radiotherapy given with curative intent) will be eligible to participate. All trial participants will receive 20 doses (called fractions) of radiotherapy. Evidence is available that suggests increasing the dose of radiotherapy given per fraction may improve both local control of the cancer and survival in some patients. However, high dose radiotherapy can damage normal tissues as well as the tumour. The dose of radiotherapy that can be used to treat lung cancer is limited by the normal tissues close to the cancer. For most of these normal tissues (lung, spinal cord and heart) the maximum safe radiotherapy dose that can be given is known. The maximum safe dose of radiotherapy for the oesophagus (gullet) is not currently known.

The trial will be split into two parts:

  1. For those participants where the oesophagus will receive a high dose of radiation due to it lying close to the cancer, the first part of the trial will establish the maximum safe dose of radiotherapy to the oesophagus. The first group of participants will receive a slightly higher dose than is currently used to treat lung cancer. If these participants do not have any significant side effects, a second group of participants will receive a slightly higher dose than the first group. This process will continue incrementally until side effects from the treatment become evident, thus demonstrating the maximum dose that can safely be given. Once the maximum safe dose to the oesophagus is known this will be classed as the recommended Phase II dose and all further patients entering the trial will receive no more than this dose to the oesophagus.
  2. For those participants where the cancer is a safe distance from their oesophagus, the highest dose of radiotherapy that does not exceed the known safe dose limits of the normal structures (lung, spinal cord and heart) will be used.

The findings of both parts of this study will determine whether increasing the dose of radiotherapy for NSCLC patients is a tolerable, safe and effective treatment. If the results are positive then this new treatment may be compared against the best currently available standard treatments in a future larger randomised (Phase III) trial.

Read the detailed description

Main inclusion criteria:

  1. Histologically or cytologically confirmed stage II - IIIb NSCLC (see appendix II)
  2. Inoperable disease (as assessed by a lung cancer MDT with thoracic surgical input) or operable but the patient refuses surgery
  3. Disease which can be encompassed within a radical radiotherapy treatment plan in keeping with standard practice at the participating centre
  4. WHO Performance Status 0 or 1 (Appendix III)
  5. Adequate respiratory function: FEV1 ≥ 1.0 litre, DLco (transfer factor) ≥ 40% of predicted and Kco (DLco/VA) > 40% predicted on baseline lung function tests
  6. Blood Haemoglobin ≥ 10g/dL
  7. No prior thoracic radiotherapy
  8. Age ≥ 16 years
  9. Considered fit to receive trial treatment
  10. Estimated life expectancy of more than 3 months
  11. Written informed consent obtained
  12. Patient consents for electronic CT scan and planning data to be used for future research

Main exclusion criteria:

  1. Medically unstable (e.g. unstable diabetes, uncontrolled hypertension, infection, hypercalcaemia or very symptomatic ischaemic heart disease)
  2. Previous or current malignant disease likely to interfere with protocol treatment
  3. Pancoast tumours
  4. Connective tissue disorders (e.g. Scleroderma, Systemic Lupus Erythematosus)
  5. Interstitial lung disease
  6. Women who are pregnant or lactating
  7. Women of childbearing potential who are not using adequate contraceptive precautions

    Primary outcome measure:

    Phase I:

    • Establish the maximum tolerated dose (MTD) to the oesophagus to use as the recommended Phase II dose.

    Phase II:

    • Toxicity rate (grade 3 and 4) at three months.

    Secondary outcome measures

    Phase I:

    • Chronic oesophagitis or stricture occurring/persisting two months or more after completion of radiotherapy

    Phase II:

    • Local control at three months (to include complete response, partial response and stable disease)
    • Feasibility
    • Time to Local Progression; measured in days from the day of trial entry to the date of first clinical evidence of progressive disease at the primary site
    • Time to distant metastases measured in days
    • Overall Survival; measured in days, from the day of trial entry to the day of death (from any cause)
    • Toxicity; pulmonary, oesophageal, spinal cord and cardiac grade 3 or 4 toxicity occurring up to three months after radiotherapy
    • Radiotherapy Quality Assurance. A detailed QA program will be in place to ensure adherence to the protocol. Major and minor deviations will be documented
03

Conditions studied

  • Locally Advanced Non-small Cell Lung Cancer

Keywords

  • radiotherapy
  • non small cell lung cancer
  • isotoxic
04

Who can participate

Ages eligible
16 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. or cytologically confirmed stage II - IIIb NSCLC (see appendix II)
  2. Inoperable disease (as assessed by a lung cancer MDT with thoracic surgical input) or operable but the patient refuses surgery
  3. Disease which can be encompassed within a radical radiotherapy treatment plan in keeping with standard practice at the participating centre
  4. 0 or 1 (Appendix III)
  5. Adequate respiratory function: ≥ 1.0 litre, DLco (transfer factor) ≥ 40% of predicted and Kco (DLco/VA) > 40% predicted on baseline lung function tests
  6. Blood ≥ 10g/dL
  7. No prior thoracic radiotherapy
  8. Age ≥ 16 years
  9. Considered fit to receive trial treatment
  10. Estimated of more than 3 months
  11. Written obtained
  12. Patient consents for electronic CT scan and planning data to be used for future research
  13. Patient is available for follow up

Exclusion criteria

Exclusion Criteria:

  1. Medically unstable (e.g. unstable diabetes, uncontrolled hypertension, infection, hypercalcaemia or very symptomatic ischaemic heart disease)
  2. Previous or current malignant disease likely to interfere with protocol treatment
  3. Pancoast tumours
  4. Connective tissue disorders (e.g. Scleroderma, Systemic Lupus Erythematosus)
  5. Interstitial lung disease
  6. Women who are pregnant or lactating
  7. Women of who are not using adequate precautions
Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

FEV1

From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
81 participants (actual)

Study arms

  • Experimental
    Group 1A

    Group 1A is where less than or equal to 6.5cm length of oesophagus is lying with the Planning Target Volume. Dose will be between 58 and 65Gy determined by current trial cohort in Phase I.

    Radiation: Radiotherapy

  • Experimental
    Group 1B

    Group 1A is where more than 6.5cm length of oesophagus is lying with the Planning Target Volume. Dose will be between 58 and 65Gy determined by current trial cohort in Phase I.

    Radiation: Radiotherapy

  • Experimental
    Phase II

    All patients will receive radiotherapy to a maximum dose of 65Gy in 20 fractions. The dose to the individual patient will be determined by their individual dose constraints for organs at risk.

    Radiation: Radiotherapy

Interventions

  • RadiationRadiotherapy

    All patients will receive radiotherapy to the primary lung tumour and any demonstrated nodal involvement. Patients will be given radiotherapy of a dose between 58 and 65Gy in 20 fractions. Dose will be determined by the patients' group.

06

What researchers measure

Primary outcomes

  1. Phase I: Establish the maximum tolerated dose (MTD) to the oesophagus to use as the recommended Phase II dose.

    Time frame: toxicity assessed up to 60 days after last Radiotherapy dose

  2. Phase II: Toxicity rate (grade 3 and 4) at three months.

    Time frame: 3 months

Secondary outcomes

  1. Phase I: Chronic oesophagitis or stricture occurring/persisting two months or more after completion of radiotherapy

    Time frame: 2 months

  2. Pase II: Local control at three months (to include complete response, partial response and stable disease)

    Time frame: 3 months

  3. Phase II: Feasibility

    Time frame: 2 years

  4. Phase II: Time to Local Progression; measured in days from the day of trial entry to the date of first clinical evidence of progressive disease at the primary site

    Time frame: 2 years

  5. Phase II: Time to distant metastases measured in days

    Time frame: 2 years

  6. Phase II: Overall Survival; measured in days, from the day of trial entry to the day of death (from any cause)

    Time frame: 2 years

  7. Phase II: Toxicity; pulmonary, oesophageal, spinal cord and cardiac grade 3 or 4 toxicity occurring up to three months after radiotherapy

    Time frame: 3 months

  8. Phase II: Radiotherapy Quality Assurance. A detailed QA program will be in place to ensure adherence to the protocol. Major and minor deviations will be documented

    Time frame: 2 years

07

Study locations

2 sites
  • Velindre Cancer Centre
    Cardiff, Glamorgan CF14 2TL, United Kingdom
  • Clatterbridge Centre for Oncology
    Liverpool, Merseyside CH63 4JY, United Kingdom
08

References and documents

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jan 2012 to primary completion in Apr 2016, 50 months.

Of 345 non-industry interventional studies with no phase under Carcinoma, Non-Small-Cell Lung, half reached primary completion within 52 months of starting (the median), counting those still running; a quarter within 28 and three quarters within 97. This study's 50 months is close to that.

Counting every sponsor, half of 361 studies reached it within 51 months; a quarter within 26 and three quarters within 97.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 17, 2012
First posted
Feb 23, 2012
StartActual
Jan 26, 2012
Primary completionActual
Apr 11, 2016
CompletionActual
Dec 31, 2018
Last update
Jan 14, 2019
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 14, 2019, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT01537991
Lead sponsor
Lisette Nixon
Responsible party
Lisette Nixon (Research Fellow (Senior Trial Manager in Solid Tumours), Velindre NHS Trust) — Sponsor-investigator
First posted
Feb 23, 2012
Start date
Jan 26, 2012
Primary completion
Apr 11, 2016
Completion
Dec 31, 2018
Last update
Jan 14, 2019

Study contacts

Jason Lester, MBBS, MRCP, FRCR
principal investigator · Velindre Cancer Centre
Gareth Griffiths, BSc, MSc, Cstat
study director · Wales Cancer Trials Unit

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jan 2019. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion